Tags : Aldeyra

Insights+

Insights+: COVID-19 Healthcare News Updates

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019. PharmaShots is keeping a track of all of the important updates in the Lifesciences sector, where […]Read More

Uncategorized

Insights+ Exclusive: COVID-19 Healthcare News Updates

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More

Insights+

Insights+: COVID-19 Healthcare News Updates

Shots: Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019 PharmaShots is keeping a track of all of the important updates in the Lifesciences sector […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (September 23– 27, 2019)

1. Incyte Reports Updated Results of Pemigatinib in P-II FIGHT-202 Trial for Patients with Previously Treated Advanced Cholangiocarcinoma Published: Sept 27, 2019 | Tags: Incyte, Reports, Updated, Results, Pemigatinib, P-II, FIGHT-202 Trial, Patients, Previously, Treated, Advanced, Cholangiocarcinoma 2.Pfizer Reports Results of Abrocitinib in P-III JADE MONO-2 Study for Moderate to Severe Atopic Dermatitis Published: Sept 27, 2019 […]Read More

Regulatory

Aldeyra’s ADX-2191 Receives FDA’s Fast Track Designation to Prevent Proliferative

Shots: The US FDA has granted FT designation to ADX-2191 for the prevention of proliferative vitreoretinopathy and provides it eligibility for Priority Review and rolling NDA submission The FDA’s FT designation facilitates the development and expedites the review of drugs that treat serious conditions, potentially accelerating patient access to new therapies ADX-2191 is an intravitreal […]Read More